Literature DB >> 35363054

A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G.

Stuart A Weinzimer1, Ryan J Bailey2, Richard M Bergenstal3, Revital Nimri4,5, Roy W Beck2, Desmond Schatz6, Louise Ambler-Osborn7, Darja Smigoc Schweiger8,9, Thekla von dem Berge10, Judy Sibayan2, Mary L Johnson3, Peter Calhoun2, Moshe Phillip4,5.   

Abstract

Background: We recently reported that use of an "advanced" hybrid closed-loop system reduced hyperglycemia without increasing hypoglycemia compared to a first-generation system. The aim of this analysis was to evaluate whether this improved performance was specifically related to better mealtime glycemic control.
Methods: We conducted a secondary analysis of postprandial glycemic control in an open-label, multinational, randomized crossover trial of 112 participants with type 1 diabetes, aged 14-29, of the Medtronic MiniMed™ 670G hybrid closed-loop system (670G) versus the Medtronic advanced hybrid closed-loop (AHCL) system, for 12 weeks each. We compared glycemic and insulin delivery metrics over a 3 h horizon across all meals to assess system performance and outcomes.
Results: Overall meal size and premeal insulin on board were similar during run-in and between 670G and AHCL arms. Compared with 670G arm, premeal, peak, and mean glucose levels were numerically lower in the AHCL arm (167 ± 23, 231 ± 23, and 177 ± 20 mg/dL vs. 175 ± 23, 235 ± 23, and 180 ± 19 mg/dL, respectively), with a trend to lower hyperglycemia level 2 in AHCL arm. Adjusting for premeal glucose level, all postmeal outcomes between 670G and AHCL were statistically similar. Prandial insulin delivery also was similar in both treatment arms (21 ± 9 vs. 23 ± 10 U), with a shift in basal/bolus ratio from 28%/71% in 670G arm to 20%/80% in AHCL arm. Conclusions: Reduced hyperglycemia with AHCL compared to 670G was not related to early postprandial glycemic excursions after adjusting for premeal glucose level (<3 h after meal), but likely to later (>3 h) postprandial or overnight improvements. Further refinements to mealtime bolus algorithms and strategies may more optimally control prandial glycemic excursions.

Entities:  

Keywords:  Adolescents; Closed-loop system; Postprandial blood glucose; Young adults

Mesh:

Substances:

Year:  2022        PMID: 35363054      PMCID: PMC9353997          DOI: 10.1089/dia.2021.0568

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   7.337


  17 in total

1.  Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.

Authors:  Sue A Brown; Boris P Kovatchev; Dan Raghinaru; John W Lum; Bruce A Buckingham; Yogish C Kudva; Lori M Laffel; Carol J Levy; Jordan E Pinsker; R Paul Wadwa; Eyal Dassau; Francis J Doyle; Stacey M Anderson; Mei Mei Church; Vikash Dadlani; Laya Ekhlaspour; Gregory P Forlenza; Elvira Isganaitis; David W Lam; Craig Kollman; Roy W Beck
Journal:  N Engl J Med       Date:  2019-10-16       Impact factor: 91.245

2.  Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study.

Authors:  Torben Biester; Ido Muller; Thekla von dem Berge; Eran Atlas; Revital Nimri; Moshe Phillip; Tadej Battelino; Natasa Bratina; Klemen Dovc; Markus F Scheerer; Olga Kordonouri; Thomas Danne
Journal:  Diabetes Obes Metab       Date:  2020-12-10       Impact factor: 6.577

3.  Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial.

Authors:  Melissa H Lee; Barbora Paldus; Sara Vogrin; Dale Morrison; Dessi P Zaharieva; Jean Lu; Hannah M Jones; Emma Netzer; Lesley Robinson; Benyamin Grosman; Anirban Roy; Natalie Kurtz; Glenn M Ward; Richard J MacIsaac; Alicia J Jenkins; David N O'Neal
Journal:  Diabetes Care       Date:  2021-08-06       Impact factor: 19.112

4.  A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.

Authors:  Richard M Bergenstal; Revital Nimri; Roy W Beck; Amy Criego; Lori Laffel; Desmond Schatz; Tadej Battelino; Thomas Danne; Stuart A Weinzimer; Judy Sibayan; Mary L Johnson; Ryan J Bailey; Peter Calhoun; Anders Carlson; Elvira Isganaitis; Rachel Bello; Anastasia Albanese-O'Neill; Klemen Dovc; Torben Biester; Kate Weyman; Korey Hood; Moshe Phillip
Journal:  Lancet       Date:  2021-01-16       Impact factor: 202.731

5.  Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.

Authors:  Satish K Garg; Stuart A Weinzimer; William V Tamborlane; Bruce A Buckingham; Bruce W Bode; Timothy S Bailey; Ronald L Brazg; Jacob Ilany; Robert H Slover; Stacey M Anderson; Richard M Bergenstal; Benyamin Grosman; Anirban Roy; Toni L Cordero; John Shin; Scott W Lee; Francine R Kaufman
Journal:  Diabetes Technol Ther       Date:  2017-01-30       Impact factor: 6.118

6.  Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

Authors:  Gregory P Forlenza; Orit Pinhas-Hamiel; David R Liljenquist; Dorothy I Shulman; Timothy S Bailey; Bruce W Bode; Michael A Wood; Bruce A Buckingham; Kevin B Kaiserman; John Shin; Suiying Huang; Scott W Lee; Francine R Kaufman
Journal:  Diabetes Technol Ther       Date:  2018-12-26       Impact factor: 6.118

7.  Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial.

Authors:  Grenye O'Malley; Laurel H Messer; Carol J Levy; Jordan E Pinsker; Gregory P Forlenza; Elvira Isganaitis; Yogish C Kudva; Laya Ekhlaspour; Dan Raghinaru; John Lum; Sue A Brown
Journal:  Diabetes Technol Ther       Date:  2021-04       Impact factor: 6.118

8.  Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes.

Authors:  Bruce A Buckingham; Mark P Christiansen; Gregory P Forlenza; R Paul Wadwa; Thomas A Peyser; Joon Bok Lee; Jason O'Connor; Eyal Dassau; Lauren M Huyett; Jennifer E Layne; Trang T Ly
Journal:  Diabetes Technol Ther       Date:  2018-08-02       Impact factor: 6.118

9.  Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study.

Authors:  Kerem Ozer; Alison M Cooper; Lily P Ahn; Cassidy R Waggonner; Thomas C Blevins
Journal:  Diabetes Technol Ther       Date:  2021-03-08       Impact factor: 6.118

10.  Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes.

Authors:  Sue A Brown; Gregory P Forlenza; Bruce W Bode; Jordan E Pinsker; Carol J Levy; Amy B Criego; David W Hansen; Irl B Hirsch; Anders L Carlson; Richard M Bergenstal; Jennifer L Sherr; Sanjeev N Mehta; Lori M Laffel; Viral N Shah; Anuj Bhargava; Ruth S Weinstock; Sarah A MacLeish; Daniel J DeSalvo; Thomas C Jones; Grazia Aleppo; Bruce A Buckingham; Trang T Ly
Journal:  Diabetes Care       Date:  2021-06-07       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.